Jaguar Health Inc
JAGX
Company Profile
Business description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Contact
200 Pine Street
Suite 400
San FranciscoCA94104
USAT: +1 415 371-8300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
49
Stocks News & Analysis
stocks
Overpriced ASX listed consumer electronics retailers
Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks
Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs
Our update on select stocks from the Semiconductors industry.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.70 | 27.80 | 0.31% |
| CAC 40 | 8,122.71 | 23.24 | 0.29% |
| DAX 40 | 23,836.79 | 68.83 | 0.29% |
| Dow JONES (US) | 47,716.42 | 289.30 | 0.61% |
| FTSE 100 | 9,720.51 | 26.58 | 0.27% |
| HKSE | 25,858.89 | 87.04 | -0.34% |
| NASDAQ | 23,365.69 | 151.00 | 0.65% |
| Nikkei 225 | 50,253.91 | 86.81 | 0.17% |
| NZX 50 Index | 13,489.15 | 56.95 | 0.42% |
| S&P 500 | 6,849.09 | 36.48 | 0.54% |
| S&P/ASX 200 | 8,614.10 | 22.30 | 0.26% |
| SSE Composite Index | 3,888.60 | 13.34 | 0.34% |